Research graph
References from Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol. Local targets link to admitted publications; unresolved targets remain external evidence.
WHO 2016 Classification of gliomas
10.1111/nan.12432 · 2018 · External reference
Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification
10.1093/neuonc/noz011 · 2019 · External reference
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
10.1093/annonc/mdx169 · 2017 · External reference
Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence
10.3389/fonc.2015.00251 · 2015 · External reference
The clinical relevance of cancer cell lines
10.1093/jnci/djt007 · 2013 · External reference
US cancer institute to overhaul tumour cell lines
10.1038/nature.2016.19364 · 2016 · External reference
Integrated classification of lung tumors and cell lines by expression profiling
10.1073/pnas.192240599 · 2002 · External reference
A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo
10.1158/0008-5472.can-15-2402 · 2016 · External reference
A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity
10.1016/j.cell.2019.11.036 · 2020 · External reference
Human primary liver cancer-derived organoid cultures for disease modeling and drug screening
10.1038/nm.4438 · 2017 · External reference
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
10.1016/j.cell.2017.11.010 · 2018 · External reference
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
10.1126/science.aao2774 · 2018 · External reference
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
10.1182/blood-2010-12-328252 · 2011 · External reference
Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma
10.1158/1078-0432.ccr-18-3034 · 2019 · External reference
Applied Precision Cancer Medicine in Neuro-Oncology
10.1038/s41598-019-56473-0 · 2019 · External reference
Lomustine and Bevacizumab in Progressive Glioblastoma
10.1056/nejmoa1707358 · 2017 · External reference
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
10.1093/neuonc/nov104 · 2015 · External reference
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
10.3389/fneur.2019.00042 · 2019 · External reference
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
10.1016/s1470-2045(18)30675-2 · 2019 · External reference
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
10.1093/neuonc/nox154 · 2018 · External reference
Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)
10.1126/scitranslmed.aan0941 · 2018 · External reference
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
2022 · External reference
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
10.1038/s41408-020-0276-7 · 2020 · External reference
Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study
10.1182/blood-2021-149331 · 2021 · External reference
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
10.1093/neuonc/nox144 · 2018 · External reference
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005 · External reference
First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
10.1200/jco.2004.11.019 · 2004 · External reference
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme
10.1002/cncr.20072 · 2004 · External reference
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
10.1159/000500135 · 2019 · External reference
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group
10.1007/bf00210791 · 1996 · External reference
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
10.1016/j.jocn.2009.12.009 · 2010 · External reference
Irinotecan therapy in adults with recurrent or progressive malignant glioma
10.1200/jco.1999.17.5.1516 · 1999 · External reference
P01.044 Impact of the addition of vinorelbine to temozolomide in the first-line treatment of pediatric high grade gliomas
10.1093/neuonc/noy139.086 · 2018 · External reference
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
10.1200/jco.2009.23.6497 · 2009 · External reference
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
10.1200/jco.2009.23.2595 · 2010 · External reference
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
10.1200/jco.2009.26.3541 · 2010 · External reference
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium
10.1002/ijc.32258 · 2019 · External reference
Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium
10.1200/jco.2016.34.15_suppl.2031 · 2016 · External reference
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
10.1073/pnas.1219747110 · 2013 · External reference
Toward precision medicine in glioblastoma: the promise and the challenges
10.1093/neuonc/nov031 · 2015 · External reference
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
10.1016/j.cell.2020.07.017 · 2020 · External reference
Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy
10.1101/gad.235515.113 · 2014 · External reference
Isolation of cancer stem cells from adult glioblastoma multiforme
10.1038/sj.onc.1208311 · 2004 · External reference
